NL301149I2 - setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Info

Publication number: NL301149I2
Authority: NL; Netherlands
Prior art keywords: setmelanotide; optionally; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2013-03-15

Application number

NL301149C

Other languages

English (en)

Other versions

NL301149I1 (nl

Original Assignee

Rhythm Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2021-12-06

Publication date

2022-11-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301149(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-12-06 Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc

2021-12-08 Publication of NL301149I1 publication Critical patent/NL301149I1/nl

2022-11-24 Publication of NL301149I2 publication Critical patent/NL301149I2/nl

Links

HDHDTKMUACZDAA-PHNIDTBTSA-N (4r,7s,10s,13r,16s,19r,22r)-22-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1h-imidazol-5-ylmethyl)-7-(1h-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20 Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](C(N[C@@H](CC=2N=CNC=2)C(=O)N1)=O)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(N)=O)C1=CC=CC=C1 HDHDTKMUACZDAA-PHNIDTBTSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
229950001912 setmelanotide Drugs 0.000 title 1
108700030852 setmelanotide Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Dispersion Chemistry (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NL301149C 2013-03-15 2021-12-06 setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301149I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361792440P	2013-03-15	2013-03-15
PCT/US2014/029421 WO2014144842A2 (en)	2013-03-15	2014-03-14	Pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
NL301149I1 NL301149I1 (nl)	2021-12-08
NL301149I2 true NL301149I2 (nl)	2022-11-24

Family

ID=50732290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301149C NL301149I2 (nl)	2013-03-15	2021-12-06	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (18)

Country	Link
US (2)	US11129869B2 (nl)
EP (2)	EP2970389B1 (nl)
JP (4)	JP6538025B2 (nl)
KR (1)	KR102378943B1 (nl)
CN (3)	CN105518021A (nl)
AU (5)	AU2014228460B2 (nl)
BR (1)	BR112015023409B1 (nl)
CA (2)	CA2906782C (nl)
DK (1)	DK2970389T3 (nl)
ES (1)	ES2825076T3 (nl)
FR (1)	FR21C1059I2 (nl)
IL (2)	IL241378B (nl)
NL (1)	NL301149I2 (nl)
NO (1)	NO2021051I1 (nl)
PL (1)	PL2970389T3 (nl)
PT (1)	PT2970389T (nl)
RU (1)	RU2690377C2 (nl)
WO (1)	WO2014144842A2 (nl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3988108A1 (en)	2011-12-29	2022-04-27	Rhythm Pharmaceuticals, Inc.	Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2020120797A (ru)	2013-03-15	2020-07-02	Ритм Фармасьютикалз, Инк.	Пептидные композиции
CA2906782C (en) *	2013-03-15	2023-10-03	Rhythm Metabolic, Inc.	Pharmaceutical compositions
EP2991616A4 (en) *	2013-04-11	2016-11-09	Univ Vanderbilt	polyplexes
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
JP6940853B2 (ja)	2015-09-30	2021-09-29	リズムファーマシューティカルズ，インコーポレイテッド	メラノコルチン４受容体経路関連障害を治療する方法
JP6701572B2 (ja) *	2016-07-05	2020-05-27	株式会社リコー	インク、収容容器、画像形成方法及び画像形成装置
JP2019526611A (ja)	2016-09-13	2019-09-19	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	非タンパク質クロストリジウム毒素組成物
MA49883A (fr)	2017-03-15	2021-04-21	Novo Nordisk As	Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
MA46990B1 (fr)	2017-08-24	2024-03-29	Novo Nordisk As	Compositions glp-1 et ses utilisations
BR112020009648A2 (pt) *	2017-11-15	2020-11-10	Rhythm Pharmaceuticals, Inc.	formulações peptídicas de liberação prolongada
WO2019219714A1 (en)	2018-05-15	2019-11-21	Novo Nordisk A/S	Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en)	2018-09-14	2020-03-19	Novo Nordisk A/S	Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
KR102087634B1 (ko) *	2018-10-11	2020-03-11	(주)바이텍	항비만용 조성물
SG11202106847SA (en) *	2019-01-04	2021-07-29	Kineta Chronic Pain Llc	Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
TW202535454A (zh)	2020-02-18	2025-09-16	丹麥商諾佛儂迪克股份有限公司	醫藥配方
CN111718408A (zh) *	2020-07-06	2020-09-29	成都圣诺生物制药有限公司	一种Setmelanotide的制备方法
JP2024532294A (ja) *	2021-08-24	2024-09-05	ザリージェンツオブザユニバーシティオブミシガン	Ｍｃ４ｒアゴニストペプチド
KR20230065921A (ko) *	2021-11-05	2023-05-12	(주)아이엠디팜	신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물
WO2023247999A1 (en) *	2022-06-24	2023-12-28	Mainline Biosciences (Shanghai) Co., Ltd.	Peptidic pain modulators and methods for producing and using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849704A (en) *	1991-12-20	1998-12-15	Novo Nordisk A/S	Pharmaceutical formulation
AU6785094A (en)	1993-05-07	1994-12-12	Sequus Pharmaceuticals, Inc.	Subcutaneous liposome delivery method
US5795587A (en) *	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731408A (en)	1995-04-10	1998-03-24	Arizona Board Of Regents On Behalf Of The University Of Arizona	Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5968895A (en) *	1996-12-11	1999-10-19	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) *	1996-12-11	2007-08-09	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
US7176279B2 (en) *	2000-06-28	2007-02-13	Palatin Technologies, Inc.	Cyclic peptide compositions and methods for treatment of sexual dysfunction
JP2005504715A (ja)	2000-12-29	2005-02-17	アドバンストインハレーションリサーチ，インコーポレイテッド	持続放出特性を有する吸入用粒子
EP1441750A4 (en)	2001-07-11	2006-10-18	Palatin Technologies Inc	LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US20040097419A1 (en) *	2002-11-19	2004-05-20	Holger Petersen	Organic compounds
FR2851563B1 (fr)	2003-02-26	2005-04-22	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr)	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
EP1644023A2 (en) *	2003-06-19	2006-04-12	Eli Lilly And Company	Melanocortin recptor 4(mc4) agonists and their uses
FR2862971B1 (fr)	2003-11-28	2006-03-24	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
KR100638041B1 (ko)	2003-12-24	2006-10-23	주식회사 삼양사	수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
FR2872165B1 (fr)	2004-06-24	2006-09-22	Sod Conseils Rech Applic	Nouveaux derives de pyrimido-benzimidazole
WO2007008684A2 (en)	2005-07-08	2007-01-18	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Ligands of melanocortin receptors
EP2286825B1 (en) *	2005-07-08	2016-09-28	Ipsen Pharma	Melanocortin receptor ligands
JP5250026B2 (ja) *	2007-05-25	2013-07-31	イプセンファルマソシエテパールアクシオンサンプリフィエ	ヒダントインで修飾したメラノコルチン受容体リガンド
AR066175A1 (es)	2007-06-15	2009-08-05	Sod Conseils Rech Applic	Ligandos del receptor de melanocortina de peptidos ciclicos
CN101980717A (zh)	2007-11-05	2011-02-23	益普生制药股份有限公司	黑皮质素治疗胰岛素敏感的应用
TW201002340A (en) *	2008-06-09	2010-01-16	Palatin Technologies Inc	Melanocortin receptor-specific peptides for treatment of obesity
KR20110025974A (ko) *	2008-06-25	2011-03-14	엔도 파마슈티컬즈, 솔루션스 아이엔씨.	이형제를 함유하는 옥트레오티드 이식물
CN101439182B (zh) *	2008-12-18	2012-02-01	北京大学	一种生长抑素受体介导的肿瘤靶向药物组合物
WO2010144344A2 (en) *	2009-06-08	2010-12-16	Palatin Technologies, Inc.	Melanocortin receptor-specific peptides
UY32690A (es) *	2009-06-08	2011-01-31	Astrazeneca Ab	Péptidos específicos para receptores de melanocortina
BR112012002445A2 (pt)	2009-08-05	2015-10-13	Ipsen Pharma Sas	uso de um agonista do receptor 4 de melanocortina.
JP2013510881A (ja)	2009-11-16	2013-03-28	イプセンファルマソシエテパールアクシオンサンプリフィエ	Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法
RU2548753C2 (ru)	2009-11-16	2015-04-20	Ипсен Фарма С.А.С.	Фармацевтические композиции лигандов рецепторов меланокортинов
CA2833676C (en)	2011-06-14	2019-04-23	Ipsen Pharma S.A.S.	A sustained-release composition containing peptides as active ingredient
JP2013046596A (ja)	2011-08-29	2013-03-07	Alpha-Nano-Medica Co Ltd	新規な複合体、それを含有する医薬及び癌の治療方法
WO2013033838A1 (en) *	2011-09-09	2013-03-14	Pharmagap Inc.	Liposomal formulations of cationic peptides and uses thereof
EP2705835A1 (en)	2012-06-08	2014-03-12	Ipsen Pharma S.A.S.	Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CA2906782C (en) *	2013-03-15	2023-10-03	Rhythm Metabolic, Inc.	Pharmaceutical compositions
RU2020120797A (ru)	2013-03-15	2020-07-02	Ритм Фармасьютикалз, Инк.	Пептидные композиции

2014
- 2014-03-14 CA CA2906782A patent/CA2906782C/en active Active
- 2014-03-14 KR KR1020157029620A patent/KR102378943B1/ko active Active
- 2014-03-14 AU AU2014228460A patent/AU2014228460B2/en active Active
- 2014-03-14 WO PCT/US2014/029421 patent/WO2014144842A2/en not_active Ceased
- 2014-03-14 EP EP14724574.0A patent/EP2970389B1/en active Active
- 2014-03-14 US US14/775,911 patent/US11129869B2/en active Active
- 2014-03-14 RU RU2015143965A patent/RU2690377C2/ru active
- 2014-03-14 PT PT147245740T patent/PT2970389T/pt unknown
- 2014-03-14 CA CA3209602A patent/CA3209602A1/en active Pending
- 2014-03-14 CN CN201480026783.9A patent/CN105518021A/zh active Pending
- 2014-03-14 DK DK14724574.0T patent/DK2970389T3/da active
- 2014-03-14 CN CN202211043877.XA patent/CN115957297A/zh active Pending
- 2014-03-14 ES ES14724574T patent/ES2825076T3/es active Active
- 2014-03-14 BR BR112015023409-7A patent/BR112015023409B1/pt active IP Right Grant
- 2014-03-14 EP EP20185463.5A patent/EP3778623A1/en active Pending
- 2014-03-14 CN CN202211043853.4A patent/CN115957296A/zh active Pending
- 2014-03-14 JP JP2016503089A patent/JP6538025B2/ja active Active
- 2014-03-14 PL PL14724574T patent/PL2970389T3/pl unknown
2015
- 2015-09-09 IL IL241378A patent/IL241378B/en unknown
2019
- 2019-01-08 AU AU2019200101A patent/AU2019200101B2/en active Active
- 2019-06-05 JP JP2019104944A patent/JP2019189619A/ja active Pending
2021
- 2021-04-30 AU AU2021202699A patent/AU2021202699A1/en not_active Abandoned
- 2021-08-13 US US17/401,929 patent/US12285460B2/en active Active
- 2021-12-03 NO NO2021051C patent/NO2021051I1/no unknown
- 2021-12-06 NL NL301149C patent/NL301149I2/nl unknown
- 2021-12-13 IL IL288961A patent/IL288961A/en unknown
- 2021-12-14 FR FR21C1059C patent/FR21C1059I2/fr active Active
2022
- 2022-02-17 JP JP2022023265A patent/JP2022065117A/ja active Pending
2023
- 2023-07-12 AU AU2023204625A patent/AU2023204625A1/en not_active Abandoned
2024
- 2024-09-27 JP JP2024169338A patent/JP2025004067A/ja active Pending
2025
- 2025-08-05 AU AU2025213562A patent/AU2025213562A1/en active Pending

Also Published As

Publication number	Publication date
AU2023204625A1 (en)	2023-08-03
CN115957297A (zh)	2023-04-14
JP2025004067A (ja)	2025-01-14
US11129869B2 (en)	2021-09-28
JP2016516062A (ja)	2016-06-02
US20220160818A1 (en)	2022-05-26
JP2019189619A (ja)	2019-10-31
AU2019200101B2 (en)	2021-02-04
AU2025213562A1 (en)	2025-08-21
NO2021051I1 (no)	2024-08-05
BR112015023409B1 (pt)	2023-11-28
FR21C1059I2 (fr)	2022-12-02
BR112015023409A2 (pt)	2017-07-18
JP2022065117A (ja)	2022-04-26
CA2906782A1 (en)	2014-09-18
KR20160020405A (ko)	2016-02-23
AU2014228460B2 (en)	2018-11-01
CN105518021A (zh)	2016-04-20
RU2690377C2 (ru)	2019-06-03
CN115957296A (zh)	2023-04-14
PL2970389T3 (pl)	2021-03-08
CA2906782C (en)	2023-10-03
FR21C1059I1 (fr)	2022-01-21
EP2970389B1 (en)	2020-08-19
RU2019116003A (ru)	2019-07-17
JP6538025B2 (ja)	2019-07-03
CA3209602A1 (en)	2014-09-18
IL288961A (en)	2022-02-01
DK2970389T3 (da)	2020-10-26
AU2019200101A1 (en)	2019-01-31
EP3778623A1 (en)	2021-02-17
ES2825076T3 (es)	2021-05-14
BR112015023409A8 (pt)	2019-12-03
IL241378B (en)	2022-01-01
EP2970389A2 (en)	2016-01-20
IL241378A0 (en)	2015-11-30
US20160022764A1 (en)	2016-01-28
HK1220702A1 (en)	2017-05-12
NL301149I1 (nl)	2021-12-08
WO2014144842A2 (en)	2014-09-18
AU2014228460A1 (en)	2015-10-01
US12285460B2 (en)	2025-04-29
WO2014144842A3 (en)	2015-04-09
KR102378943B1 (ko)	2022-03-25
PT2970389T (pt)	2020-10-21
RU2015143965A (ru)	2017-04-24
AU2021202699A1 (en)	2021-05-27

Publication	Publication Date	Title
NL301341I2 (nl)	2025-10-02	eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301245I2 (nl)	2023-11-20	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301161I2 (nl)	2022-04-06	zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301155I2 (nl)	2022-02-23	abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301327I2 (nl)	2025-07-17	Belzutifan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder belzutifan
NL301238I2 (nl)	2023-10-04	Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301329I2 (nl)	2025-09-09	Lazertinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301279I2 (nl)	2024-08-01	Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301342I2 (nl)	2025-11-10	Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL301326I2 (nl)	2025-07-31	imetelstat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301224I2 (nl)	2023-08-16	Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NL301047I2 (nl)	2023-08-01	fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301260I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300980I2 (nl)	2021-06-17	Doravirine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300947I2 (nl)	2018-09-26	Bictegravir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bictegravirnatrium
ZA201905426B (en)	2022-07-27	Drug combinations